Core Viewpoint - Chutian Technology Co., Ltd. reported a revenue decline of 6.60% year-on-year for the first three quarters of the year, but achieved a significant net profit increase of 145.11% due to strategic adjustments and cost reduction measures [1] Group 1: Financial Performance - For the first three quarters, the company achieved a revenue of 3.896 billion yuan, down 6.60% year-on-year, while the net profit attributable to shareholders was 84.4635 million yuan, up 145.11% [1] - In the third quarter, the company reported a revenue of 1.479 billion yuan, an increase of 10.17% year-on-year, and a net profit of 96.7681 million yuan, up 192.50% [1] - The company's operating costs for the first three quarters were 2.682 billion yuan, a decrease of 13.19% year-on-year, with selling and administrative expenses also declining [3] Group 2: Strategic Adjustments - Chutian Technology has actively adjusted its business strategy since the second half of last year, focusing on international market expansion and reducing low-margin projects domestically [1] - The company has segmented its global market into five regions and tailored its sales services to enhance international competitiveness, achieving breakthroughs in Europe, the Middle East, and Southeast Asia [2] - The company plans to implement a series of operational reforms starting in the second half of 2024, including optimizing product solutions, streamlining procurement costs, and improving production efficiency [3] Group 3: Market Expansion and Innovation - The company hosted the 2025 Vietnam Biopharmaceutical Summit, enhancing its regional visibility and laying a solid foundation for future market expansion [2] - Chutian Technology participated in the World Pharmaceutical Raw Materials and Machinery Exhibition in Frankfurt, showcasing innovative core equipment to the global market [3] - The company is advancing its layout in niche markets such as medical aesthetics and peptides, aiming to open new avenues for revenue growth [3]

Group 1 - The core point of the article is that Chutian Technology (SZ 300358) held its sixth board meeting on October 27, 2025, to review the proposal for the third quarter report of 2025 [1] - For the first half of 2025, Chutian Technology's revenue composition shows that the pharmaceutical industry accounts for 99.72%, while other businesses account for 0.28% [1] - As of the report date, Chutian Technology has a market capitalization of 5.6 billion yuan [1]

智通财经APP讯，楚天科技(300358.SZ)发布2025年三季度报告，该公司前三季度营业收入为38.96亿 元，同比减少6.60%。归属于上市公司股东的净利润为8446.35万元，同比增长145.11%。归属于上市公 司股东的扣除非经常性损益的净利润为2863.27万元，同比增长113.55%。基本每股收益为0.1431元。 ...

楚天科技股份有限公司（以下简称"公司"）于 2025 年 10 月 27 日召开第六 届董事会第三次会议，审议通过了《关于公司 2025 年第三季度报告的议案》。公 司 2025 年第三季度报告全文于 2025 年 10 月 28 日在中国证监会指定的创业板信 息披露网站 http://www.cninfo.com.cn 上披露，敬请投资者查阅。 | 证券代码:300358 | 证券简称:楚天科技 | 公告编号：2025-060 号 | | --- | --- | --- | | 债券代码:123240 | 债券简称:楚天转债 | | 楚天科技股份有限公司 2025 年第三季度报告披露提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特此公告。 楚天科技股份有限公司董事会 2025 年 10 月 27 日 ...

| 证券代码：300358 | 证券简称：楚天科技 | 公告编号：2025-059 号 | | --- | --- | --- | | 债券代码：123240 | 债券简称：楚天转债 | | 经审议，董事会认为：公司 2025 年第三季度报告内容真实、准确、完整地 反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 本议案已经公司董事会审计委员会审议通过。 具体内容详见同日巨潮资讯网（www.cninfo.com.cn）披露的《公司 2025 年第三季度报告》。 表决情况：同意 13 票，反对 0 票，弃权 0 票。 二、备查文件 楚天科技股份有限公司 第六届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 楚天科技股份有限公司（以下简称"公司"）第六届董事会第三次会议于 2025 年 10 月 27 日以现场及通讯结合方式召开，会议通知于 2025 年 10 月 17 日 以电子邮件方式送达给全体董事。本次会议由公司董事长唐岳先生召集，应出席 董事 13 人，实际出席董事 13 人，公司非董事高管列席会议，符合《公司法 ...

楚天科技公告，第三季度营收为14.79亿元，同比增长10.17%；净利润为9676.81万元，同比增长 192.50%。前三季度营收为38.96亿元，同比下降6.60%；净利润为8446.35万元，同比增长145.11%。 ...

楚天科技股份有限公司 2025 年第三季度报告 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担 个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 1 | 证券代码：300358 证券简称：楚天科技 | 公告编号：2025-061 号 | | --- | --- | | 债券代码：123240 债券简称：楚天转债 | | 楚天科技股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 楚天科技股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末比上 年初至报告期末 | | | --- | --- | --- | --- | --- | | | | 增减 | 年同期增减 | ...

Core Viewpoint - The company, Chutian Technology, has committed to transparently disclosing its operational status in accordance with relevant standards and regulations, while also enhancing its value promotion and management capabilities to protect investor interests [2] Group 1 - Chutian Technology responded to investor inquiries on October 24, indicating its adherence to disclosure requirements [2] - The company plans to further improve its value communication and management skills [2] - The focus is on maintaining the interests of a broad base of investors [2]

Core Viewpoint - Chutian Technology (300358) is enhancing contract quality management, cost control, and delivery efficiency to improve the gross margin of its various products [1] Group 1 - The company is focusing on strengthening contract quality management [1] - The company is implementing measures to enhance cost control [1] - The company aims to improve delivery efficiency [1] - The company is continuously working to increase the gross margin of its products [1]

Group 1 - The core point of the article is that Chutian Technology is collaborating with Heyuan Biotechnology to provide solutions for the large-scale production of a globally innovative "rice-derived" product [2] - Chutian Technology confirmed on the investor interaction platform that Heyuan Biotechnology is one of its clients, and they are assisting in the establishment of the world's first plant-derived recombinant human albumin injection production line [2] - Chutian Technology's subsidiary, Chutian Yuanchuang, is supplying several sets of fully automated chromatography columns and associated online liquid chromatography systems, as well as multiple ultrafiltration systems for the project [2]